CoChat

Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies (STRONG-HF): Rationale and Design for a Multicentre, Randomized, Parallel-Group Study

Open access
Kimmoun, Antoine, Cotter, Gad, Davison, Beth, Takagi, Koji, Addad, Faouzi, Celutkiene, Jelena, Chioncel, Ovidiu, Solal, Alain Cohen, Diaz, Rafael, Damasceno, Albertino, Duengen, Hans-Dirk, Filippatos, Gerasimos, Goncalvesova, Eva, Merai, Imad, Metra, Marco, Ponikowski, Piotr, Privalov, Dmitry, Sliwa, Karen, Sani, Mahmoud Umar, Voors, Adriaan A., Shogenov, Zaur, Mebazaa, Alexandre · 2019 · European Journal of Heart Failure
Cited by 63

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims: Patients admitted for acute heart failure (HF) are at high risk of readmission and death, especially in the 90 days following discharge. We aimed to assess the safety and efficacy of early optimization of oral HF therapy with beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) or angiotensin receptor–neprilysin inhibitors (ARNi), and mineralocorticoid receptor antagonists (MRA) on 90-day clinical outcomes in patients admitted for acute HF. Methods: In a multicentre, randomized, open-label, parallel-group study, a total of 900 patients will be randomized in a 1:1 ratio to either ‘usual care’ or ‘high-intensity care’. Patients enrolled in the usual care arm will be discharged and managed according to usual clinical practice at the site. In the high-intensity care arm, doses of oral HF medications – including a BB, ACEi or ARB, and MRA – will be up-titrated to 50% of recommended doses before discharge and to 100% of recommended doses within 2 weeks of discharge. Up-titration will be delayed if the patients develop worsening symptoms and signs of congestion, hyperkalaemia, hypotension, bradycardia, worsening of renal function or significant increase in N-terminal pro-B-type natriuretic peptide between visits. The primary endpoint is 90-day all-cause mortality or HF readmission. Conclusions: STRONG-HF is the first study to assess whether rapid up-titration of evidence-based guideline-recommended therapies with close follow-up in a large cohort of patients discharged from an acute HF admission is safe and can affect adverse outcomes during the first 90 days after discharge. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT03412201.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.1575

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Kimmoun, A., Cotter, G., Davison, B., Takagi, K., Addad, F., Celutkiene, J., Chioncel, O., Solal, A. C., Diaz, R., Damasceno, A., Duengen, H.-D., Filippatos, G., Goncalvesova, E., Merai, I., Metra, M., Ponikowski, P., Privalov, D., Sliwa, K., Sani, M. U., Voors, A. A., Shogenov, Z., & Mebazaa, A.
Venue
European Journal of Heart Failure
Published
2019-08-19
Volume
21
Issue
11
Pages
1459-1467
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2969953468
Cited by
63
References
7
FWCI
3.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.